The Abramson Cancer Center of the University of Pennsylvania
Last Modified: March 2, 2010
Thank you for your interest in making a donation to OncoLink.
OncoLink was founded in 1994 by Penn cancer specialists with a mission to help cancer patients, families, health care professionals and the general public get accurate cancer-related information at no charge.
There is an incredible team of devoted doctors, nurses, cancer team members, and web developers that continually update OncoLink. Most of our core specialists volunteer their time. All of our information is free to people with cancer, their families and friends. As a non-profit organization, we rely upon voluntary donations and educational grants to provide these valuable services.
Please join our team
Help us to empower cancer patients world wide by supporting the cancer education efforts at OncoLink.
100% of your tax-deductible donation will be devoted to ongoing development and dissemination of educational resources on OncoLink.
Jun 16, 2011 - The U.S. Food and Drug Administration has approved the Inform Dual ISH test, a genetic test to determine whether women with breast cancer are human epidermal growth factor receptor 2-positive and therefore candidates for trastuzumab (Herceptin).